Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.142362 http://scihub22266oqcxt.onion/10.1172/jci.insight.142362 32870820!7566699!32870820     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight 2020 ; 5 (19): ä Nephropedia Template TP {{tp|p=32870820|t=2020. A simple protein-based surrogate neutralization assay for SARS-CoV-2 |pdf=|usr=}}{{32870820}} gab.com Text A simple protein-based surrogate neutralization assay for SARS-CoV-2 JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=32870820 #FOAvip Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but the duration of this response and how it correlates with clinical outcomes has not been completely characterized. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike protein receptor binding domain (RBD) with its receptor, angiotensin-converting enzyme 2 (ACE2). The assay serves as a surrogate neutralization assay and is performed on the same platform and in parallel with an ELISA for the detection of antibodies against the RBD, enabling a direct comparison. The results obtained with our assay correlate with those of 2 viral-based assays, a plaque reduction neutralization test (PRNT) that uses live SARS-CoV-2 virus and a spike pseudotyped viral vector-based assay. Twit Text FOAVip A simple protein-based surrogate neutralization assay for SARS-CoV-2 ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=32870820 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32870820 #FOAvip English Wikipedia <ref>{{Cite pmid|32870820}}</ref> A simple protein-based surrogate neutralization assay for SARS-CoV-2 #MMPMID32870820 Abe KT; Li Z; Samson R; Samavarchi-Tehrani P; Valcourt EJ; Wood H; Budylowski P; Dupuis AP 2nd; Girardin RC; Rathod B; Wang JH; Barrios-Rodiles M; Colwill K; McGeer AJ; Mubareka S; Gommerman JL; Durocher Y; Ostrowski M; McDonough KA; Drebot MA; Drews SJ; Rini JM; Gingras AC JCI Insight 2020[Oct]; 5 (19): ä PMID32870820show ga Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but the duration of this response and how it correlates with clinical outcomes has not been completely characterized. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike protein receptor binding domain (RBD) with its receptor, angiotensin-converting enzyme 2 (ACE2). The assay serves as a surrogate neutralization assay and is performed on the same platform and in parallel with an ELISA for the detection of antibodies against the RBD, enabling a direct comparison. The results obtained with our assay correlate with those of 2 viral-based assays, a plaque reduction neutralization test (PRNT) that uses live SARS-CoV-2 virus and a spike pseudotyped viral vector-based assay. |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/blood[MESH] |Area Under Curve[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/*immunology/*therapy[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Humans[MESH] |Immunization, Passive/methods[MESH] |Neutralization Tests[MESH] |Pandemics[MESH] |Pneumonia, Viral/*immunology/*therapy[MESH] |Regression Analysis[MESH] |Sampling Studies[MESH] |Spike Glycoprotein, Coronavirus/*immunology[MESH] |Treatment Outcome[MESH]A simple protein-based surrogate neutralization assay for SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing